Navigation Links
FDA Wants New Diabetes Drugs Tested for Heart Risks
Date:12/17/2008

Companies must now show their drugs don't increase chances of cardiac trouble

WEDNESDAY, Dec. 17 (HealthDay News) -- The U.S. Food and Drug Administration is now asking all companies looking for approval of new type 2 diabetes medications to undertake studies that determine whether they cause cardiovascular problems.

This new guidance document, announced Wednesday, comes on the heels of reports that two commonly prescribed blood sugar-lowering drugs already on the market, Avandia and Actos, increase the risk of heart failure and, in the case of Avandia, increase the risk of heart attack.

"The guidance document will help industry evaluate the cardiovascular risk associated with new therapies under development to treat type 2 diabetes," Dr. Mary Parks, director of the Division of Metabolism and Endocrinology Products in FDA's Center for Drug Evaluation and Research said during a Wednesday afternoon teleconference.

Parks noted that diabetic patients are already at an increased risk for cardiovascular problems. But the agency believes it's important to insure that new drugs don't compound the risk further, she said. More than 23 million people in the United States have been diagnosed with type 2 diabetes.

The new guidance reflects the decision of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee, which in July called for studies of the cardiovascular risks of new diabetic drugs.

According to the new guidance, companies looking to have new diabetes drugs approved by the FDA must submit data from phase II and phase III trials that show these drugs are not associated with an "unacceptable risk" of cardiovascular disease, Parks said.

Parks noted that these new requirements mean that companies will have to enroll more patients in clinical trails than in the past, especially more older patients who are already at risk for heart disease.

Trials assessing cardiovascular risks will have to go on for at least a year, Parks said. "The trials have to be of an adequate duration so that we can get a sense of long-term risk," she explained.

The change in the approval process does mean that it will take longer for new drugs to reach the market. "It's safe to assume that requiring a longer duration of trials, and a bolstering of the sample size, that it will add some years to the clinical development program," Parks said.

The FDA has sent 100 to 150 letters to companies with new diabetes products under development to alert them of the new guidance, which takes effect immediately, Parks said.

This guidance document does not affect drugs already on the market. These drugs will be the subject of another guidance document, Parks said. When that document will be released isn't known. "It's on our to-do list," she said.

More information

For more information on diabetes, visit the U.S. National Institute on Diabetes and Kidney Diseases .



SOURCES: Dec. 17, 2008, teleconference with Mary Parks, M.D., director, Division of Metabolism and Endocrinology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New Poll Shows Public Worried About Medicare Cuts Impact on Seniors, Boomers - Wants Congress To Act
2. Adverse housing conditions contribute to diabetes risk
3. RAND finds cases of undiagnosed diabetes drop sharply
4. UCLA researchers identify markers that may predict diabetes in still-healthy people
5. Diabetes appears to increase risk of death for patients with acute coronary syndromes
6. Discovery of sugar sensor in intestine could benefit diabetes
7. Despite overeating, morbidly obese mice gain protection against diabetes
8. Heart Attack Boosts Diabetes Risk
9. Obesity Doesnt Always Equal Diabetes
10. Sugary Sodas High in Diabetes-Linked Compound
11. Treating diabetes during pregnancy can break link to childhood obesity
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Wants New Diabetes Drugs Tested for Heart Risks
(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson Insurance and Financial ... financial preparation services, is providing an update on a charitable event that began ... Rescue is a locally recognized nonprofit that provides shelter and care for animals ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board ... Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will ... Dr. Puffer’s retirement at the end of 2018. Upon assuming the role of President ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical ... the primary prevention of cardiovascular diseases during the 15th Annual Women’s Health ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. ... big data solutions, today announced that its MyDario product is expected to ... TV listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, ... ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound energy ... ... Jim Bertolina, PhD ... Tom Tefft ... executive Josh Stopek , PhD, who has led R&D and business development teams at ...
Breaking Medicine Technology: